Quantitative Method for the In Vivo Testing of Fibrinolytic Agents: Effect of Intravenous Trypsin on Radioactive Thrombi and Emboli

¹ Department of Pharmacology, Philadelphia College of Pharmacy and Science; Graduate School, the Harrison Department of Surgery, University of Pennsylvania Medical School, Philadelphia, Pa., and the Roswell Park Memorial Institute, Buffalo, N. Y.

Quantitative methods for testing fibrinolytic agents in vivo are described. Methods based on the incorporation into the clot of P³² labeled blood cells or Cr⁵¹ labeled erythrocytes were found to be unsatisfactory. Clots were produced with I¹³¹ labeled fibrinogen. Dissolution of a clot resulted in decrease of radioactivity. This was recorded by placing segments of blood vessels in a special lead shield containing a scintillation detector head, connected to a radiation rate meter and an Esterline recorder. Pulmonary, peripheral and coronary emboli were produced by injecting radioactive clots produced and ground, in vitro. Using these methods it was found that maximal tolerated doses of trypsin showed no significant fibrinolytic effect.

This article has been cited by other articles:

				C. M. Ambrus, J. L. Ambrus, H. Gastpar, S. D. Sharma, O.W. Suh, R. H. Moore, and P. Williams The Role of Fibrinolysis in the Therapy of Peripheral Vascular Disease Angiology, July 1, 1984; 35(7): 436 - 442. [Abstract] [PDF]

				R. V. Chapple and H. O. Singher ROLE OF FIBRINOLYTIC AGENTS IN THROMBOTIC DISEASES JAMA, May 21, 1960; 173(3): 221 - 225. [Abstract] [PDF]

				J. E. Sokal, J. L. Ambrus, and C. M. Ambrus TREATMENT OF THROMBOSIS WITH FIBRINOLYSIN (PLASMIN) JAMA, November 8, 1958; 168(10): 1314 - 1323. [Abstract] [PDF]